ADC Therapeutics SA (NYSE:ADCT) filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, covering the company's financial condition and operations through the third quarter.
Key Highlights
- Share count: ADC Therapeutics reported 140,661,880 common shares outstanding as of November 2, 2026.
- Listing: The company's common shares, par value CHF 0.08 per share, are registered on the New York Stock Exchange under the symbol ADCT.
- Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
- Incorporation: ADC Therapeutics SA is incorporated in Switzerland, with principal executive offices located in Epalinges, Switzerland.
- Key product: The filing references ZYNLONTA, noting a purchase and sale agreement with entities managed by HealthCare Royalty Management, LLC ("HCR") that the company disclosed has a negative effect on cash generated from ZYNLONTA sales and licensing agreements.
- Debt: The filing discloses indebtedness under a loan agreement with affiliates and/or funds managed by Oaktree Capital Management, L.P. and Owl Rock Capital Advisors LLC, with Blue Owl Opportunistic Master Fund I, L.P. serving as administrative agent.
ADC Therapeutics Q3 2026 Quarterly Filing: Key Disclosures
ADC Therapeutics SA, a Switzerland-incorporated biopharmaceutical company whose common shares trade on the New York Stock Exchange, submitted its condensed consolidated financial statements and management discussion for the quarter and nine months ended September 30, 2026. According to the filing, the company had 140,661,880 common shares outstanding as of November 2, 2026, and its shares carry a par value of CHF 0.08 per share.
The filing identifies ZYNLONTA as a commercial product and discloses that a purchase and sale agreement with entities managed by HealthCare Royalty Management, LLC ("HCR") has, in the company's characterization, a "negative effect on the amount of cash that we are able to generate from sales of, and licensing agreements involving, ZYNLONTA and on our attractiveness as an acquisition target." The company also disclosed existing indebtedness under a loan agreement with affiliates and/or funds managed by Oaktree Capital Management, L.P. and Owl Rock Capital Advisors LLC, with Blue Owl Opportunistic Master Fund I, L.P. acting as administrative agent, noting associated restrictive covenants.
Among the risk factors referenced in the filing, the company cited "the substantial net losses that we have incurred since our inception," an expectation to "continue to incur losses for the foreseeable future," and the need to raise additional capital to fund operations. The filing also noted uncertainties related to international trade policies, including tariffs, sanctions, trade barriers, and most favored nation drug pricing. The forward-looking statements contained in the report are subject to the company's cautionary language and are described as dependent on factors over which the company may have no or limited control.
What Was Disclosed
ADC Therapeutics SA filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 140,661,880 shares outstanding, its ZYNLONTA product, the HCR royalty agreement, existing loan obligations, and ongoing risk factors including anticipated continued net losses.




Please wait processing your request...